D L Cooper

List of Publications by Year in descending order

55 papers	1,062 citations	394390 19 h-index	434170 31 g-index
55 all docs	55 docs citations	55 times ranked	906 citing authors

#	Article	IF	Citations
1	Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study. Patient Preference and Adherence, 2015, 9, 1549.	1.8	91
2	Selfâ€reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (Pâ€FiQ) study. Haemophilia, 2017, 23, 556-565.	2.1	90
3	Haemophilia Experiences, Results and Opportunities (HERO) Study: survey methodology and population demographics. Haemophilia, 2014, 20, 44-51.	2.1	86
4	Treatment outcomes, quality of life, and impact of hemophilia on young adults (aged 18â€“30 years) with hemophilia. American Journal of Hematology, 2015, 90, S3-10.	4.1	53
5	Effect of Acute Bleeding on Daily Quality of Life Assessments in Patients with Congenital Hemophilia with Inhibitors and Their Families: Observations from the Dosing Observational Study in Hemophilia. Value in Health, 2012, 15, 916-925.	0.3	47
6	Haemophilia Experiences, Results and Opportunities (<scp>HERO</scp>) Study: Influence of haemophilia on interpersonal relationships as reported by adults with haemophilia and parents of children with haemophilia. Haemophilia, 2014, 20, e287-95.	2.1	46
7	Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patientâ€reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (Pâ€FiQ) study. European Journal of Haematology, 2018, 100, 5-13.	2.2	37
8	Impact of pain and functional impairment in <scp>US</scp> adults with haemophilia: Patientâ€reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (Pâ€FiQ) study. Haemophilia, 2018, 24, 261-270.	2.1	36
9	Use of recombinant activated factor <scp>VII</scp> in patients with Glanzmann's thrombasthenia: a review of the literature. Haemophilia, 2014, 20, 464-471.	2.1	35
10	Evaluation of bleeding disorders in patients with Noonan syndrome: a systematic review. Journal of Blood Medicine, 2018, Volume 9, 185-192.	1.7	35
11	Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004â€“2008). Haemophilia, 2012, 18, 990-996.	2.1	30
12	Impact of hemophilia B on quality of life in affected men, women, and caregiversâ€”Assessment of patientâ€reported outcomes in the Bâ€<scp>HERO</scp>â€S study. European Journal of Haematology, 2018, 100, 592-602.	2.2	30
13	Haemophilia Experiences, Results and Opportunities (<scp>HERO</scp>) study: treatmentâ€related characteristics of the population. Haemophilia, 2015, 21, e26-38.	2.1	29
14	Impact of mild to severe hemophilia on education and work by <scp>US</scp> men, women, and caregivers of children with hemophilia B: The Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (Bâ€HEROâ€S) study. European Journal of Haematology, 2017, 98, 18-24.	2.2	27
15	Internal consistency and item-total correlation of patient-reported outcome instruments and hemophilia joint health score v2.1 in US adult people with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Patient Preference and Adherence, 2017, Volume 11, 1831-1839.	1.8	27
16	Prevalence and impact of obesity in people with haemophilia: Review of literature and expert discussion around implementing weight management guidelines. Haemophilia, 2017, 23, 812-820.	2.1	25
17	Management of <scp>US</scp> men, women, and children with hemophilia and methods and demographics of the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (Bâ€<scp>HERO</scp>â€S) study. European Journal of Haematology, 2017, 98, 5-17.	2.2	25
18	Patient/Caregiverâ€reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE). Haemophilia, 2012, 18, 392-399.	2.1	23

#	Article	IF	Citations
19	Factors associated with pain severity, pain interference, and perception of functional abilities independent of joint status in <scp>US</scp> adults with hemophilia: Multivariable analysis of the Pain, Functional Impairment, and Quality of Life (Pâ€FiQ) study. European Journal of Haematology, 2018, 100, 25-33.	2.2	21
20	Construct validity of patient-reported outcome instruments in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Patient Preference and Adherence, 2017, Volume 11, 1369-1380.	1.8	20
21	Known-group validity of patient-reported outcome instruments and hemophilia joint health score v2.1 in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Patient Preference and Adherence, 2017, Volume 11, 1745-1753.	1.8	17
22	Impact of mild to severe hemophilia on engagement in recreational activities by US men, women, and children with hemophilia B: The Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (Bâ€HEROâ€S) study. European Journal of Haematology, 2017, 98, 25-34.	2.2	16
23	Unmet needs in the transition to adulthood: 18- to 30-year-old people with hemophilia. American Journal of Hematology, 2015, 90, S17-S22.	4.1	15
24	Reliability of patient-reported outcome instruments in US adults with hemophilia: the Pain, Functional Impairment and Quality of life (P-FiQ) study. Patient Preference and Adherence, 2017, Volume 11, 1603-1612.	1.8	15
25	Phenotypical variability in congenital FVII deficiency follows the ISTH-SSC severity classification guidelines: a review with illustrative examples from the clinic. Journal of Blood Medicine, 2018, Volume 9, 211-218.	1.7	14
26	Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC) . Journal of Blood Medicine, 2019, Volume 10, 335-340.	1.7	14
27	Ranges and drivers of risk associated with sports and recreational activities in people with haemophilia: results of the Activityâ€Intensityâ€Risk Consensus Survey of US physical therapists. Haemophilia, 2018, 24, 5-26.	2.1	12
28	Perioperative management of haemophilia B: A critical appraisal of the evidence and current practices. Haemophilia, 2017, 23, 821-831.	2.1	11
29	Impact of haemophilia on patients with mildâ€toâ€moderate disease: Results from the Pâ€FiQ and Bâ€HEROâ€S studies. Haemophilia, 2021, 27, 8-16.	2.1	11
30	Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry. American Journal of Hematology, 2017, 92, 646-652.	4.1	10
31	Patientâ€reported outcomes and joint status across subgroups of <scp>US</scp> adults with hemophilia with varying characteristics: Results from the Pain, Functional Impairment, and Quality of Life (Pâ€FiQ) study. European Journal of Haematology, 2018, 100, 14-24.	2.2	10
32	Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: The experience of the Hemostasis and Thrombosis Research Society (HTRS) Registry (2004â€“2008). Pediatric Blood and Cancer, 2013, 60, 1178-1183.	1.5	9
33	Continuous infusion of recombinant activated factor VII: a review of data in congenital hemophilia with inhibitors and congenital factor VII deficiency. Journal of Blood Medicine, 2018, Volume 9, 227-239.	1.7	9
34	Hemophilia and sexual health: results from the HERO and B-HERO-S studies . Patient Related Outcome Measures, 2019, Volume 10, 243-255.	1.2	9
35	Identified unmet needs and proposed solutions in mildâ€toâ€moderate haemophilia: A summary of opinions from a roundtable of haemophilia experts. Haemophilia, 2021, 27, 25-32.	2.1	9
36	Identification of patients with congenital hemophilia in a large electronic health record database. Journal of Blood Medicine, 2017, Volume 8, 131-139.	1.7	7

#	Article	IF	Citations
37	Identification of people with acquired hemophilia in a large electronic health record database. Journal of Blood Medicine, 2017, Volume 8, 89-97.	1.7	7
38	Reliability and validity of patientâ€reported outcome instruments in US adults with hemophilia B and caregivers in the Bâ€HEROâ€S study. European Journal of Haematology, 2018, 101, 781-790.	2.2	7
39	Recombinant activated factor <scp>VII</scp> in approved indications: Update on safety. Haemophilia, 2018, 24, e275-e277.	2.1	7
40	Awareness, Care and Treatment In Obesity maNagement to inform Haemophilia Obesity Patient Empowerment (ACTIONâ€TOâ€HOPE): Results of a survey of US haemophilia treatment centre professionals. Haemophilia, 2020, 26, 20-30.	2.1	6
41	Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries. American Journal of Hematology, 2017, 92, 940-945.	4.1	5
42	Neuropsychological function in children with hemophilia: A review of the Hemophilia Growth and Development Study and introduction of the current eTHINK study. Pediatric Blood and Cancer, 2020, 67, e28004.	1.5	5
43	Mild-severe hemophilia B impacts relationships of US adults and children with hemophilia B and their families: results from the B-HERO-S study . Patient Related Outcome Measures, 2019, Volume 10, 257-266.	1.2	4
44	A global quantitative survey of hemostatic assessment in postpartum hemorrhage and experience with associated bleeding disorders. International Journal of Women's Health, 2017, Volume 9, 477-485.	2.6	3
45	Correlations between patient-reported outcomes and self-reported characteristics in adults with hemophilia B and caregivers of children with hemophilia B: analysis of the B-HERO-S study . Patient Related Outcome Measures, 2019, Volume 10, 299-314.	1.2	3
46	Hemophilia without prophylaxis: Assessment of joint range of motion and factor activity. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1035-1045.	2.3	3
47	Impact of Pain and Functional Impairment in US Adult People with Hemophilia (PWH): Patient-Reported Outcomes and Musculoskeletal Evaluation in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. Blood, 2015, 126, 39-39.	1.4	3
48	Awareness, Care and Treatment In Obesity maNagement to inform Haemophilia Obesity Patient Empowerment (ACTIONâ€TOâ€HOPE): Results of a survey of US patients with haemophilia and obesity (PwHO) and their partners and caregivers. Haemophilia, 2020, 26, 3-19.	2.1	3
49	Evaluating the psychosocial impact of hemophilia B: The Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (Bâ€<scp>HERO</scp>â€S) study. European Journal of Haematology, 2017, 98, 3-4.	2.2	2
50	Psychosocial Impact and Disease Management in Patients with Congenital Factor VII Deficiency . Journal of Blood Medicine, 2020, Volume 11, 297-303.	1.7	2
51	Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study . Journal of Blood Medicine, 2019, Volume 10, 391-398.	1.7	1
52	What can we learn from using formal patientâ€reported outcome instruments to assess pain, functional impairment, anxiety, and depression in <scp>US</scp> adults with hemophilia?. European Journal of Haematology, 2018, 100, 3-4.	2.2	0
53	Educational needs of hematologists and laboratory professionals regarding factor activity assays. Journal of Blood Medicine, 2018, Volume 9, 51-59.	1.7	0
54	Efficacy of EHL N9-GP for on-demand treatment of bleeding episodes in hemophilia B: analysis of pivotal trial data . Journal of Blood Medicine, 2019, Volume 10, 243-250.	1.7	0

#	Article	IF	Citations
55	Disease Burden in Patients with Glanzmann's Thrombasthenia: Perspectives from the Glanzmann's Thrombasthenia Patient/Caregiver Questionnaire. Journal of Blood Medicine, 2020, 11, 289-295.	1.7	0